{"id":6783,"date":"2024-05-02T18:04:49","date_gmt":"2024-05-02T12:34:49","guid":{"rendered":"https:\/\/lakshmishree.com\/blog\/?p=6783"},"modified":"2024-05-02T18:04:55","modified_gmt":"2024-05-02T12:34:55","slug":"indegene-ipo-details","status":"publish","type":"post","link":"https:\/\/lakshmishree.com\/blog\/indegene-ipo-details\/","title":{"rendered":"Indegene IPO Details - Complete Overview of Indegene Limited IPO"},"content":{"rendered":"\n

Indegene<\/strong> IPO Price: <\/strong>\u20b9430 to \u20b9452
IPO Date Range:<\/strong> 6 May, 2024 - 8 May, 2024<\/p>\n\n\n\n

\n
\n
\n
\n
\"\"<\/figure>\n<\/div><\/div>\n<\/div>\n<\/div>\n\n\n\n
\n

Foundation & Business Essence<\/h2>\n\n\n\n

Founded in 1998, Indegene Limited is a leading provider of digital services for the life sciences industry. Offering comprehensive solutions across drug development, clinical trials, regulatory submissions, pharmacovigilance, and sales\/marketing support, the company facilitates the modernization of operations for biopharmaceutical, emerging biotech, and medical device companies. <\/p>\n<\/div>\n<\/div>\n\n\n\n

Services <\/h2>\n\n\n\n

Indegene's services span various categories, including Enterprise Commercial Solutions, Omnichannel Activation, Enterprise Medical Solutions, and Enterprise Clinical Solutions. Their subsidiary, DT Consulting, assists life sciences firms in managing digital transformations, ensuring enhanced customer experiences. Notably, the company was honored with the Platinum Level award at the 2023 Healthy Workplace Conference and Awards, a prestigious recognition by Arogya World India Trust in collaboration with the Public Health Foundation of India, underscoring their commitment to workplace wellness.<\/p>\n\n\n\n

Clientele<\/h2>\n\n\n\n

Indegene boasts a robust clientele, including the top 20 biopharmaceutical companies globally by revenue for the Financial Year 2023, as per Everest Report. Demonstrating their strong client relationships, the company earned over 69.00% of its total revenue from operations in recent years from these top-tier clients. With a total of 65 active clients as of December 31, 2023, Indegene's revenue spectrum reflects diverse engagement levels, ranging from clients generating between US$0.25 million to over US$25 million in revenues during the preceding 12 months. This client-centric approach underscores Indegene's prominence in driving digital transformation within the life sciences sector.<\/p>\n\n\n\n

Bidding Starts In<\/h2>\n\n\n\n
\n
-<\/div>
DAYS<\/div><\/div>
-<\/div>
HOURS<\/div><\/div>
-<\/div>
MINUTES<\/div><\/div>
-<\/div>
SECONDS<\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n
APPLY NOW<\/span><\/path><\/svg>

Dream Big, Start with an IPO. Choose Lakshmishree.<\/p><\/a><\/div>\n\n\n\n

Indegene IPO Specifics:<\/h2>\n\n\n\n
\n
IPO Date<\/td>May 6, 2024 to May 8, 2024<\/td><\/tr>
Listing Date<\/td>Monday, May 13, 2024<\/td><\/tr>
Face Value<\/td>\u20b92 per share<\/td><\/tr>
Price Band<\/td>\u20b9430 to \u20b9452 per share<\/td><\/tr>
Lot Size<\/td>33 Shares<\/td><\/tr>
Total Issue Size<\/td>40,746,891 shares
(aggregating up to \u20b91,841.76 Cr)<\/td><\/tr>
Fresh Issue<\/td>16,814,159 shares
(aggregating up to \u20b9760.00 Cr)<\/td><\/tr>
Offer For Sale<\/td>23,932,732 shares
(aggregating up to \u20b91,081.76 Cr)<\/td><\/tr>
Employee Discount<\/td>Rs 30 per share<\/td><\/tr>
Issue Type<\/td>Book Built Issue IPO<\/td><\/tr>
Listing At<\/td>BSE, NSE<\/td><\/tr>
Share holding pre issue<\/td>222,435,091<\/td><\/tr>
Share holding post issue<\/td>239,249,250<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n

Indegene Limited IPO Lot Size<\/h2>\n\n\n\n

Bidders have the opportunity to bid for a minimum of 33 shares, with the option to increase in multiples. The table below outlines the minimum and maximum investment thresholds for both retail investors and High Net Worth Individuals (HNIs), specifying the corresponding number of shares and amounts involved.<\/p>\n\n\n\n

\n
Application<\/th>Lots<\/th>Shares<\/th>Amount<\/th><\/tr><\/thead>
Retail (Min)<\/td>1<\/td>33<\/td>\u20b914,916<\/td><\/tr>
Retail (Max)<\/td>13<\/td>429<\/td>\u20b9193,908<\/td><\/tr>
S-HNI (Min)<\/td>14<\/td>462<\/td>\u20b9208,824<\/td><\/tr>
S-HNI (Max)<\/td>67<\/td>2,211<\/td>\u20b9999,372<\/td><\/tr>
B-HNI (Min)<\/td>68<\/td>2,244<\/td>\u20b91,014,288<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n

Indegene IPO Reservation<\/h2>\n\n\n\n
\n
QIB Shares Offered<\/td>Not more than 50% of the Net offer<\/td><\/tr>
Retail Shares Offered<\/td>Not less than 35% of the Offer<\/td><\/tr>
NII (HNI) Shares Offered<\/td>Not less than 15% of the Offer<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n

Indegene IPO Timetable (Important Dates)<\/h2>\n\n\n\n
\n
IPO Open Date<\/td>Monday, May 6, 2024<\/td><\/tr>
IPO Close Date<\/td>Wednesday, May 8, 2024<\/td><\/tr>
Basis of Allotment<\/td>Thursday, May 9, 2024<\/td><\/tr>
Initiation of Refunds<\/td>Friday, May 10, 2024<\/td><\/tr>
Credit of Shares to Demat<\/td>Friday, May 10, 2024<\/td><\/tr>
Listing Date<\/td>Monday, May 13, 2024<\/td><\/tr>
Cut-off time for UPI mandate confirmation<\/td>5 PM on May 8, 2024<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n

Don't Miss Out!<\/h2>
<\/div>

Whether you're a seasoned investor or just starting out, Lakshmishree ensures you don't miss out on premier IPO opportunities. Dive into the future of investing with Lakshmishree.<\/p><\/div>\n\n\n\n

\n
APPLY NOW<\/a><\/div>\n<\/div>\n\n\n\n

Indegene Limited IPO Financial Information<\/h2>\n\n\n\n

Between the fiscal years ending on March 31, 2023, and March 31, 2022, Indegene Limited experienced a notable uptick in revenue, marking a growth of 39.85%. Concurrently, the company witnessed a substantial increase in profit after tax (PAT), which surged by 63.43% during the same period.<\/p>\n\n\n\n

\n
Period Ended<\/th>31 Mar 2021<\/th>31 Mar 2022<\/th>31 Mar 2023<\/th>31 Dec 2023<\/th><\/tr><\/thead>
Assets<\/td>596.04<\/td>1353.47<\/td>2203.87<\/td>2518.15<\/td><\/tr>
Revenue<\/td>996.92<\/td>1690.50<\/td>2364.10<\/td>1969.75<\/td><\/tr>
Profit After Tax<\/td>149.41<\/td>162.82<\/td>266.10<\/td>241.90<\/td><\/tr>
Net Worth<\/td>324.51<\/td>763.90<\/td>1063.72<\/td>1327<\/td><\/tr>
Reserves & Surplus<\/td>324.19<\/td>763.55<\/td>1019.43<\/td>1282.65<\/td><\/tr>
Total Borrowing<\/td>24.76<\/td>18.24<\/td>394.34<\/td>399.33<\/td><\/tr><\/tbody><\/table>
Amount in \u20b9 Crore<\/small><\/figcaption><\/figure>\n<\/div>\n\n\n\n

Key Performance Indicator - Indegene IPO<\/h2>\n\n\n\n
\n
KPI<\/th>Values<\/th><\/tr><\/thead>
Market Cap (Rs Cr)<\/td>10814.07 Cr.<\/td><\/tr>
P\/E (x)<\/td>37.78<\/td><\/tr>
Debt\/ Equity<\/td>0.3<\/td><\/tr>
EPS<\/td>11.96<\/td><\/tr>
RoNW<\/td>18.23%<\/td><\/tr><\/tbody><\/table><\/figure>\n<\/div>\n\n\n\n

Objects of the Issue:<\/strong><\/h2>\n\n\n\n

The company intends to allocate the Net Proceeds towards the following objectives:<\/p>\n\n\n\n